Pemvidutide Research for MASH (Metabolic Dysfunction-Associated Steatohepatitis)
An evidence-based overview of research examining Pemvidutide in the context of mash (metabolic dysfunction-associated steatohepatitis). This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 IMPACT trial (NCT05989711) met its MASH-resolution primary endpoint at 24 weeks: 52% MASH resolution without fibrosis worsening at 1.8 mg vs 20% placebo (and 58% at 1.2 mg). The co-primary fibrosis-improvement endpoint was not met at 24 weeks. FDA Fast Track designation granted November 2022.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pemvidutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.